NDAVAGINALINSERT, EXTENDED RELEASE
Approved
Mar 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
CERVIDIL (dinoprostone) by Ferring Pharmaceuticals is hormone. Approved for cervical ripening, induction of labor, vaginal delivery. First approved in 1995.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CERVIDIL (dinoprostone) is a prostaglandin analog vaginal insert for cervical ripening and labor induction in pregnant women. It works by stimulating prostaglandin F2α production, which sensitizes the uterus to oxytocin and promotes cervical softening, dilation, and effacement. The extended-release formulation allows for controlled local delivery to the cervix.
LOE Approaching
As LOE approaches, the brand team will shift focus to life-cycle management and differentiation strategies; team size may contract unless line extensions are pursued.
Mechanism of Action
hormone. In pregnancy, dinoprostone is secreted continuously by the fetal membranes and placenta and plays an important role in the final events leading to the initiation of labor including cervical ripening. Dinoprostone stimulates the production of prostaglandin F 2α ( PGF 2α), which sensitizes…
Pharmacologic Class:
Prostaglandin Analog
Indications (3)
Worked on CERVIDIL at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.